logo
Cavitation Technologies, Inc. Signs an Agreement with BMI Group to Advance 'Forever Chemicals' Removal Using Chemical Free Proprietary Technology

Cavitation Technologies, Inc. Signs an Agreement with BMI Group to Advance 'Forever Chemicals' Removal Using Chemical Free Proprietary Technology

CHATSWORTH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Cavitation Technologies, Inc. ('CTi' or the 'Company') (OTCQB: CVAT), a pioneer in advanced fluid processing and water treatment, today announced that it has entered into an agreement with BMI Group, a Canadian environmental solutions provider specializing in large-scale water and wastewater treatment projects.
Clean water has never been more critical, and never more at risk. Industry has disposed of at least 60 million pounds of 'forever chemicals' (PFAS) in the U.S. over the past five years. These are among the most dangerous chemicals and they can't be seen, smelled, or tasted, yet they're everywhere: in our water, soil, and air.
The problem isn't finding PFAS, it's removing them.
Under the agreement, BMI Group will hold certain exclusivity rights within its territory and is required to achieve a minimum of $1 million in annual sales. This collaboration aims to deliver a more effective and scalable process for removing 'forever chemicals' (PFAS) that pose significant environmental and health risks. The agreement includes rental fees for the units and the initial shipment of both the High-Pressure Nano-Reactor® and Cavitation Non-Thermal Plasma™ systems, which have already been delivered.
'PFAS contamination is one of the most persistent and costly environmental challenges of our time,' said Neil Voloshin, CEO of Cavitation Technologies, Inc. 'By combining our patented High-Pressure Nano-Reactor® with Cavitation Non-Thermal Plasma™, we've developed an innovative solution that's both scalable and effective.'
Current PFAS removal methods fall short:
High-Pressure Nano-Reactor® + Cavitation Non-Thermal Plasma™ Advantage:
The technology is also designed to:
A Multi-Industry Impact
Beyond PFAS removal, CTi's High-Pressure Nano-Reactor® and Cavitation Non-Thermal Plasma™ are driving change across multiple sectors, including industrial water and wastewater treatment, Bitcoin mining, agriculture, pharmaceuticals, high-precision electronics, and desalination. Together, these technologies deliver chemical-free, scalable treatment that removes a wide range of contaminants, improves water quality, and reduces operational costs for industries worldwide.
About BMI Group
Founded in 2005, BMI Group is a Canadian-based engineering and environmental solutions company specializing in the design, construction, and operation of water and wastewater treatment facilities. With a track record of delivering high-performance, sustainable infrastructure, BMI Group serves municipalities, industrial clients, and government agencies across North America.
About Cavitation Technologies, Inc.
Founded in 2007, Cavitation Technologies, Inc. (OTCQB: CVAT), is a leading ESG company that designs and manufactures innovative flow-through nano-technology systems for fluid processing applications worldwide. The technology is designed for fluid processing across multiple industries: water treatment and remediation, agriculture, pharmaceuticals, oil & gas, edible oil refining, renewable fuels, alcoholic and non-alcoholic beverage enhancement, PFAS removal, and now, high-performance computing and digital asset infrastructure.
Our core products are Nano Reactor® systems, with scalable capacities ranging from 10 to 500 gallons per minute (GPM), and our latest advancement, Cavitation Non-Thermal Plasma™ technology, which currently operates at 25 GPM and is scalable to a larger flow. These systems effectively eliminate bacteria and viruses, reduce TDS levels, lower turbidity, and offer the removal of PFAS in multiple water remediation applications.
CTi holds over 40 patents issued domestically and internationally.
Follow our social media for real-time updates:
Visit our websites for more information:
Call or email us:
Cavitation Technologies Inc.
818-718-0905
[email protected]
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as ''may,'' ''should,'' ''potential,'' ''continue,'' ''expects,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''estimates,'' and similar expressions. These forward-looking statements are based largely on the Company's expectations and are subject to many risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a variety of factors including, among others, our ability to install as anticipated, the state of the economy, the competitive environment and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties, there can be no assurances that the forward-looking statements contained in this press release will transpire or prove to be accurate. The information in this release is provided only as of the release date, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/17a999e8-dc58-4165-93ac-3b0d31a026f4
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time18 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time18 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store